QCM
NTLA icon

Quantinno Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Quantinno Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509K Buy
39,709
+6,266
+19% +$79.8K ﹤0.01% 2702
2025
Q4 		$301K Buy
33,443
+9,145
+38% +$126K ﹤0.01% 2830
2025
Q3 		$420K Buy
24,298
+4,669
+24% +$57.5K ﹤0.01% 2175
2025
Q2 		$184K Buy
19,629
+8,185
+72% +$67.2K ﹤0.01% 2385
2025
Q1 		$81.4K Buy
+11,444
New +$116K ﹤0.01% 2061

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Quantinno Capital Management's NTLA Position: Q1 2026 in Review

Quantinno Capital Management increased its Intellia Therapeutics (NTLA) stake by 19% in Q1 2026, buying an estimated $79.8K and bringing the position to 39,709 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #2702.

Quantinno Capital Management first reported a position in NTLA in Q1 2025 and has held it in 5 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Quantinno Capital Management held 39,709 shares of Intellia Therapeutics worth $509K as of Q1 2026.
  • Quantinno Capital Management bought 6,266 Intellia Therapeutics shares in Q1 2026, an estimated $79.8K.
  • Intellia Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #2702 holding.
  • Quantinno Capital Management first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.